APRENasdaqPharmaceutical PreparationsFiscal year ends December 31

Aprea Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.53−0.05 (-8.88%)

Close on Oct 19, 2026

Market cap: $28.47M
P/E (TTM): –
Dividend yield: –

Earnings

Next report expected Nov 11, 2026, before market open (estimated from past report dates)

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2026 Ended Jun 30, 2026	Aug 12, 2026	Before market open	–	–	–
Q1 FY2026 Ended Mar 31, 2026	May 13, 2026	Before market open	–	–	–
Q4 FY2025 Ended Dec 31, 2025	Mar 16, 2026	Before market open	–	–	–
Q3 FY2025 Ended Sep 30, 2025	Nov 12, 2025	Before market open	–	–	–
Q2 FY2025 Ended Jun 30, 2025	Aug 12, 2025	Before market open	–	–	–
Q1 FY2025 Ended Mar 31, 2025	May 14, 2025	Before market open	–	–	–
Q4 FY2024 Ended Dec 31, 2024	Mar 25, 2025	Before market open	$205.82K	$-0.49	–
Q3 FY2024 Ended Sep 30, 2024	Nov 7, 2024	Before market open	$400.00K	$-0.64	–
Q2 FY2024 Ended Jun 30, 2024	Aug 12, 2024	Before market open	$600.00K	$-0.58	–
Q1 FY2024 Ended Mar 31, 2024	May 14, 2024	Before market open	$380.57K	$-0.67	–
Q4 FY2023 Ended Dec 31, 2023	Mar 26, 2024	Before market open	$14.08K	$-0.92	–

Press releases

Announcements Aprea Therapeutics filed with the SEC

Aug 28, 2026, 8:30 AM ET
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Other events · EX-99.1 to Form 8-K
Aug 12, 2026, 8:35 AM ET
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
May 13, 2026, 6:35 AM ET
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
Apr 1, 2026, 8:45 AM ET
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Regulation FD disclosure · EX-99.1 to Form 8-K
Mar 30, 2026, 5:30 PM ET
Announces Oversubscribed $30 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mar 30, 2026, 5:30 PM ET
Therapeutics Highlights Positive Emerging Clinical Activity for WEE1
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Mar 16, 2026, 8:15 AM ET
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
Feb 18, 2026, 8:30 AM ET
Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051
Other events · EX-99.1 to Form 8-K
Jan 29, 2026, 4:16 PM ET
Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Jan 29, 2026, 4:16 PM ET
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Jan 29, 2026, 4:16 PM ET
EX-99.3 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Dec 9, 2025, 4:30 PM ET
Aprea Therapeutics Announces $3.1 Million Private
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Nov 12, 2025, 8:35 AM ET
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
Results of operations · Other events · EX-99.1 to Form 8-K
Oct 24, 2025, 8:35 AM ET
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
Other events · EX-99.1 to Form 8-K
Oct 15, 2025, 8:05 AM ET
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
Other events · EX-99.1 to Form 8-K
Sep 8, 2025, 7:45 AM ET
Transforming DDR Inhibition into Patient
Other events · EX-99.1 to Form 8-K
Aug 12, 2025, 8:05 AM ET
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
Results of operations · Other events · EX-99.1 to Form 8-K
May 14, 2025, 8:05 AM ET
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
Results of operations · Other events · EX-99.1 to Form 8-K
Mar 25, 2025, 8:40 AM ET
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Feb 5, 2025, 8:30 AM ET
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
Other events · EX-99.1 to Form 8-K
Nov 7, 2024, 8:38 AM ET
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
Oct 23, 2024, 9:00 AM ET
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Oct 9, 2024, 8:45 AM ET
Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1
Results of operations · Other events · EX-99.1 to Form 8-K
Aug 12, 2024, 8:40 AM ET
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
Jun 17, 2024, 8:45 AM ET
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Other events · EX-99.1 to Form 8-K
May 14, 2024, 8:40 AM ET
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
Results of operations · Other events · EX-99.1 to Form 8-K